In focus · trending topic

anti-DLL4

4 stories · following the connections

OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer

By Nasdaq OMXFeb 13, 2017, 1:31 PM UTC

OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients

By Nasdaq OMXJan 4, 2017, 1:32 PM UTC

OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients

By Nasdaq OMXJan 4, 2017, 1:32 PM UTC

OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients

By Nasdaq OMXJan 4, 2017, 1:32 PM UTC